Recent Updates
Recently added Catalysts
AQST Negative Sentiment

AQUESTIVE THERAPEUTICS, INC. (AQST) INVESTOR ALERT Investors With Large Losses in Aquestive Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Key Takeaway: Investors in Aquestive Therapeutics, Inc. have been alerted to a securities class action lawsuit filed on their behalf by Bernstein Liebhard LLP. The lawsuit targets alleged misrepresentations made by the company concerning its New Drug Application for Anaphylm. Affected shareholders are advised to file papers by May 4, 2026, if they wish to serve as lead plaintiffs. Legal representation for the class action is provided on a contingency fee basis, meaning no fees are incurred unless successful.
Price reaction · baseline $4.26 (2026-03-05 close) · hit after-hours · 1 other AQST headline(s) in the window, move may be shared
day 0 close
-0.9%

Market Sentiment Analysis

CONCERNS & RISKS

  • A shareholder has filed a securities class action lawsuit against Aquestive Therapeutics.
  • The lawsuit alleges misrepresentations regarding the company's New Drug Application for Anaphylm (Dibutepinephrine) sublingual film.
  • Investors are encouraged to take legal action due to significant losses incurred.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
21%
average across 5 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
DESF
Phase 2 · Allergic Reaction

Full Press Release Details

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (Nasdaq: AQST) between June 16, 2025 and January 8, 2026, inclusive.
For more information, submit a form at Aquestive Therapeutics, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030.
If you wish to serve as lead plaintiff for the Class, you must file papers by May 4, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
According to the lawsuit, Defendants made misrepresentations concerning Aquestive’s New Drug Application for Anaphylm (Dibutepinephrine) sublingual film.
About Bernstein Liebhard:
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2026 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Frequently Asked Questions

What is the purpose of the class action lawsuit against Aquestive?

The lawsuit aims to address misrepresentations made by Aquestive regarding its New Drug Application for Anaphylm.

Who can participate in the class action lawsuit?

Investors who acquired Aquestive securities between June 16, 2025, and January 8, 2026, can participate.

What is the deadline to file as lead plaintiff?

The deadline to file papers to serve as lead plaintiff is May 4, 2026.

Will shareholders incur fees for representation in the lawsuit?

No, all representation in the lawsuit is on a contingency fee basis, meaning shareholders pay no fees.

How can I contact Bernstein Liebhard LLP for more information?

You can email Peter Allocco at pallocco@bernlieb.com or call (212) 951-2030.

Last updated: Mar 6, 2026